Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

NORTHAMPTON, MA / ACCESS Newswire / April 22, 2025 / At Boehringer Ingelheim, every day is Earth Day because we're continuously working to reduce our environmental footprint while serving the ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Dublin, April 22, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Boehringer Ingelheim 2025" company profile has been added to ResearchAndMarkets.com's offering. The report ...

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers Ingelheim, Germany and Amsterdam, the Netherlands, 23 April 2025 – ...

Boehringer Ingelheim has released data on its patient reach, sales, and investments during 2024, and is looking ahead to the company’s anticipated offerings for the rest of 2025. In a press release on ...

Ingelheim, Germany and Amsterdam, the Netherlands, 23 April 2025 – Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality ...

Boehringer Ingelheim strengthens footprintin Swiss biotech innovation hub. Basel, Switzerland, Thursday, 03.04.2025 – Today NBETherapeutics (NBE)a wholly owned subsidiary of Boehringer Ingelheim ...